VANCOUVER GENERAL HOSPITAL
CSU PHARMACEUTICAL SCIENCES
SPECIAL ACCESS DRUG DATA SHEET

DRUG NAME
levetiracetam

ALTERNATE NAME
Keppra

MANUFACTURER
Hospira

STRENGTH
500 mg/5 mL

DOSAGE FORM
Injectable

INDICATIONS

- For the treatment of status epilepticus in patients whom conventionally available anti-epileptics cannot be used or do not work sufficiently AND/OR in whom oral levetiracetam is not a feasible option

DOSAGE AND ADMINISTRATION

- 1,000–3,000 mg IV per day, given in two divided doses
    - Status epilepticus: 1500 mg IV over 5 min as loading dose
      Must administer as a primary line
    - Maintenance: 500 mg to 1500 mg IV over 15 min to 30 min given twice a day
      Maximum infusion rate 2 to 5 mg/kg/min
- Dilute in 100 mL NS or D5W
- Stable for 24 hours at room temperature

KNOWN SIDE EFFECTS*

- Somnolence, fatigue, coordination difficulties, behaviour abnormalities (depression, nervousness, anxiety and emotional lability), withdrawal seizures, asthenia, infection dizziness

SPECIAL PRECAUTIONS

- Contraindicated in patients with hypersensitivity to levetirecetam
- Levetiracetam is renally cleared. Monitor renal function and adjust dose accordingly.
- This document is a summary. Refer to the product monograph for more information.
- This levetiracetam injection is not available on the Canadian market. Approval must be obtained from the Health Canada Special Access Programme prior to use.

***REPORT ANY ADVERSE DRUG REACTIONS TO CSU PHARMACEUTICAL SCIENCES**

OCT2015 (HP/JY)

References:
Neurocritical Care 2012;17(1):3-23
Seizure 2000;9(2):80-87
Neurology 2008;70(22 pt 2):2166-70
Epilepsy Research 2015;114:13-22
Epilepsia 2006;47(11):1128